NowotworyPub Date : 2023-10-25DOI: 10.5603/njo.96724
Ariadna Feliu, David Ritchie, Joachim Schuz, Carolina Espina
{"title":"The European Code Against Cancer – new evidence and recommendations","authors":"Ariadna Feliu, David Ritchie, Joachim Schuz, Carolina Espina","doi":"10.5603/njo.96724","DOIUrl":"https://doi.org/10.5603/njo.96724","url":null,"abstract":"Cancer is a major public health concern in the European Union (EU). There were 2.7 million new cancer cases and 1.3 million deaths in the EU; of them, around 40% could be prevented. Primary prevention is the most cost-effective long-term strategy for cancer control. The European Code Against Cancer (ECAC, 4 th edition) is a health education tool aimed at raising awareness about evidence-based cancer prevention actions among EU citizens. The ECAC describes 12 ways individuals can reduce their cancer risk. Awareness of the ECAC (4 th ed.) was low (2–21%) and, therefore, efforts are needed to improve cancer prevention awareness throughout the region. Civil society and other stakeholders’ engagement is key to improve cancer prevention in the region. Our aim is to propose recommendations to improve future ECAC editions to achieve an increase in cancer prevention literacy in the EU.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134971960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NowotworyPub Date : 2023-10-25DOI: 10.5603/njo.96564
Marta Dec, Wojciech Figiel, Paweł Andruszkiewicz, Michał Grąt
{"title":"The influence of fluid therapy on short and long – term outcome in patients undergoing liver resection for malignant indications","authors":"Marta Dec, Wojciech Figiel, Paweł Andruszkiewicz, Michał Grąt","doi":"10.5603/njo.96564","DOIUrl":"https://doi.org/10.5603/njo.96564","url":null,"abstract":"Although fluid therapy in hepatic surgery affects postoperative course and morbidity, there is paucity of unequivocal guidelines in the literature as to which of three fluid strategies: liberal, restrictive or goal directed should be used. We performed a review of literature regarding fluid management strategies in major abdominal procedures, focusing on hepatic surgery . The quantity and quality of fluids infused perioperatively is often dependant on the preference of the physician , institutional experience and practices. Liberal fluid regimen carries the risk of impaired wound healing and prolonged ileus, furthermore in liver surgery it may increase blood loss. Restrictive fluid therapy is the mainstay of the anesthetic management in hepatic resections, keeping the central venous pressure low controls outflow from the liver and results in decrease in intraoperative blood loss. In recent years, goal directed fluid therapy ( GDFT), as a component of enhancend recovery pathways after surgery (ERAS) programs, has gained popularity. It is based on the concept of hemodynamic optimization in order to ensure optimal tissue perfusion and oxygen delivery. Furthermore, fluid infusion strategy should be individualized in terms of unique pathophysiology of the patient (eg. cirrhosis) and the specific requirements of the surgical technique (laparoscopic procedures). Controversy regarding often contradictory data, leaves the clinician at a loss as to which fluid strategy will best serve the patient. Therefore, it is imperative to design and conduct clinical trials in homogenous group of patients to define the optimal type and amount of fluid for patients undergoing hepatic surgery.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"90 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134971604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NowotworyPub Date : 2023-10-25DOI: 10.5603/njo.96405
Maciej Dyrbuś, Ilona Skoczylas, Aleksandra Majsnerowska, Mariusz Gąsior, Mateusz Tajstra
{"title":"Pharmacological prevention methods in patients with cardiovascular disease with breast cancer – when, how, and for whom?","authors":"Maciej Dyrbuś, Ilona Skoczylas, Aleksandra Majsnerowska, Mariusz Gąsior, Mateusz Tajstra","doi":"10.5603/njo.96405","DOIUrl":"https://doi.org/10.5603/njo.96405","url":null,"abstract":"Breast cancer is the leading cause of cancer-related deaths in women worldwide. Patients with breast cancer are at an increased risk of cardiovascular toxicity, presently defined as cancer therapy-related cardiovascular toxicity (CTR-CVT). This article provides a summary of the current knowledge on pharmacological cardiovascular prevention in breast cancer patients. The ESC guidelines on cardio-oncology have defined CTR-CVT. Baseline risk stratification with widely accepted risk scores is essential to identify patients at higher risk of CTR-CVT. The guidelines recommend the use of angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs), and beta-blockers as preventive medications in high-risk patients. Clinical trials have shown ambiguous results for ACE-I/ARBs and beta-blockers in reducing cardiotoxicity, while co-administration of ACE-I/ARBs and beta-blockers did not show additional benefits in preventing cardiac dysfunction. Further research is needed to verify the efficacy of novel cardioprotective medication and optimize pharmacological strategies for cardiovascular prevention in breast cancer patients.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"40 6","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134971951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NowotworyPub Date : 2023-10-16DOI: 10.5603/njo.96782
Maciej D. Bugajski, Agata Popow-Gierba, Małgorzata Wysocka-Malik
{"title":"A diagnostic dilemma of low-grade adrenal cortical carcinoma in young female patient","authors":"Maciej D. Bugajski, Agata Popow-Gierba, Małgorzata Wysocka-Malik","doi":"10.5603/njo.96782","DOIUrl":"https://doi.org/10.5603/njo.96782","url":null,"abstract":"A 33-year-old woman with incidentally diagnosed abdominal mass in ultrasound has undergone evaluation with an MRI exam and 18F-FDG PET-CT scan (fig. 1, 2). Medical history was only significant for hypertension and oligomenorrhea from 6 months. The endocrinology studies were nonspecific. Initial differential diagnosis were ganglioneuroma, adrenal cortical carcinoma (ACC) and pheochromocytoma. Clinical and imaging features supporting diagnosis of ganglioneuroma were age of patient (median age at diagnosis 31 years), normal / lower values of adrenal hormones, generally well-circumscribed margins, progressive enhancement and persistent in delayed phase (assessed in T1w before and after dynamic administration of gadobutrol contrast), no evidence of distant metastasis [1, 2]. Those in favor of ACC consisted of hemorrhage on T1w, heterogeneous T2w signal – higher than a liver, enhanced density of periadrenal fat [1, 2]. The diagnosis of pheochromocytoma was less confident due to relatively low signal on T2w. High FDG uptake (SUV max 9.0) suggested malignant character. For all pathologies parameters like lesion size (11 cm), no presence of drop of signal during out-of-phase sequence, no evidence of IVC invasion, local compressive symptoms showed imaging overlap [1, 2]. Diffusion weighted imaging (DWI) were of high signal within the lesion, with low signal on corresponding ADC maps. However, DWI does not add significant value to differentiating between benign and malignant adrenal lesions according to available evidence [2]. ACC is a very rare and aggressive malignancy, with annual incidence varying between 0.5–2 cases per million [2].","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136183100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NowotworyPub Date : 2023-10-13DOI: 10.5603/njo.95279
Jeeja Hernole, Rajeswari Narayanappa
{"title":"Interactions between Notch and Matrix metalloproteinases: role in cancer","authors":"Jeeja Hernole, Rajeswari Narayanappa","doi":"10.5603/njo.95279","DOIUrl":"https://doi.org/10.5603/njo.95279","url":null,"abstract":"Notch has its importance in the development and maintenance of cells and tissues. Either gain or loss of notch signalling causes a wide range of abnormalities including cancer. To activate Notch signalling, the notch ligand must be processed by the family of proteases, ADAMs. Until recently, exclusively in the cancer context, a class of proteases, Matrix metalloproteinases (MMPs) were known to cleave notch and trigger downstream signalling. Notch was found to regulate the expression of Matrix metalloproteinases (MMPs) through crosstalk. Studies have revealed that interactions between notch and MMPs are associated with aggressive cancer traits such as invasion, metastasis, angiogenesis, and endothelial mesenchymal transition. In this review, we recapitulate the studies which reveal the Notch-MMP interactions that have provided new perception into the mechanisms behind Notch-mediated aggressiveness in cancers.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135923529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NowotworyPub Date : 2023-09-05DOI: 10.5603/njo.a2023.0032
Michał Masłowski, Konrad Stawiski, Adam Zięba, Damian Mikulski, Julia Bednarek, Jacek Fijuth
{"title":"Predicting neutropenia dynamics after radiation therapy in multiple myeloma patients receiving first-line bortezomib-based chemotherapy – a pilot study","authors":"Michał Masłowski, Konrad Stawiski, Adam Zięba, Damian Mikulski, Julia Bednarek, Jacek Fijuth","doi":"10.5603/njo.a2023.0032","DOIUrl":"https://doi.org/10.5603/njo.a2023.0032","url":null,"abstract":"Introduction. Radiation therapy (RT) is a useful modality for achieving local control and symptom relief in patients with multiple myeloma (MM), but its use can result in adverse effects such as neutropenia, which may be aggravated by prior chemotherapy. Material and methods. In this retrospective study, we analyzed 530 complete blood count results of 32 MM patients who underwent RT for symptomatic bone pain between cycles or after completing first-line bortezomib-based chemotherapy (VCD). To evaluate the dynamics of neutrophil count (ANC) changes, we developed a generalized additive model (GAM) using initial ANC, dosage (BED10), and treatment volume (PTV) as predictors. Results. Our GAM model demonstrated that ANC nadir after RT can be expected approximately 16 days after treatment initiation. The delivery of 8 Gy in 1 fraction resulted in the lowest ANC nadir, while a dose of 30 Gy in 10–15 fractions was deemed the safest. For PTV = 1000 cm3, an initial ANC level of at least 1.42 × 103/μl was associated with no incidence of severe neutropenia irrespective of the fractionation scheme. Longer courses allowed for treatment delivery without significant neutropenia even with an initial ANC of 1.23 × 103/μl on the day of RT initiation. Conclusions. Our model could aid in optimizing treatment strategies for MM patients receiving RT and chemotherapy. Further research is needed to validate our findings and evaluate the feasibility of implementing this model in clinical practice.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"110 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135363977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NowotworyPub Date : 2023-09-05DOI: 10.5603/njo.a2023.0029
Anna Rygula, Michał Kowalski, Marcin Ziętek
{"title":"Uterine leiomyosarcoma metastatic to the pancreas","authors":"Anna Rygula, Michał Kowalski, Marcin Ziętek","doi":"10.5603/njo.a2023.0029","DOIUrl":"https://doi.org/10.5603/njo.a2023.0029","url":null,"abstract":"","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135363974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NowotworyPub Date : 2023-09-05DOI: 10.5603/njo.95859
Piotr Smoter, Marcin Kotulski, Katarzyna Smoter, Tadeusz Wróblewski, Michał Grąt
{"title":"Liver transplantation in primary liver tumors","authors":"Piotr Smoter, Marcin Kotulski, Katarzyna Smoter, Tadeusz Wróblewski, Michał Grąt","doi":"10.5603/njo.95859","DOIUrl":"https://doi.org/10.5603/njo.95859","url":null,"abstract":"As transplant medicine has evolved in recent decades so too have the indications for liver transplantation (LT). Active or suspected malignancy has stopped being considered as a contraindication for organ transplantation, and nowadays LT plays a major role in the treatment strategies of liver tumors. It offers excellent long-term outcomes for certain patients with hepatocellular carcinoma (HCC) and carefully selected patients with cholangiocarcinoma (CCA), who undergo neoadjuvant chemoradiatotherapy. In certain clinical courses of rare primary liver tumors, hepatic epithelioid haemangio-endothelioma (HEHE) and hepatic adenoma (HA), liver transplantation is also considered the best treatment option. Optimal patient selection has become the key issue to achieve the best possible outcomes and to deal with the alleviating shortage of organs. The recent tendency to incorporate markers of tumor biology into selection criteria, rather than simply focusing on tumor size and number, has led to further extension of indications for LT in patients with liver malignancy. This review article focuses on the current place of liver transplantation in the treatment strategy for patients with primary liver tumors, mainly primary liver cancers.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135363980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NowotworyPub Date : 2023-09-05DOI: 10.5603/njo.a2023.0035
Łukasz Balwicki, Marta Miller, Magdalena Cedzyńska, Irena Przepiórka, Jarosław Pinkas, Wioleta Tomczak, Tomasz Zdrojewski
{"title":"Expert consensus statement on tobacco control sustainability in Poland","authors":"Łukasz Balwicki, Marta Miller, Magdalena Cedzyńska, Irena Przepiórka, Jarosław Pinkas, Wioleta Tomczak, Tomasz Zdrojewski","doi":"10.5603/njo.a2023.0035","DOIUrl":"https://doi.org/10.5603/njo.a2023.0035","url":null,"abstract":"Introduction. Tobacco use poses a significant public health threat in Poland, with high rates of consumption and detrimental effects on individuals. Tobacco is responsible for one-third of all cancer deaths in Poland. This study aimed to develop an expert consensus statement on tobacco control sustainability in Poland. Material and methods. An expert consensus hybrid meeting was conducted, gathering national tobacco control experts from various fields. The meeting utilized the Index of Tobacco Control Sustainability (ITCS) to identify critical indicators for a sustainable national tobacco control program. Results. Key recommendations include developing a comprehensive tobacco control strategy and program, establishing inter-governmental coordination, strengthening civil society involvement, creating a dedicated Tobacco Control Unit, allocating government annual funding for tobacco control operations, and strengthening organizational resistance to tobacco industry interference. Conclusions. Poland needs to build the institutional capacity and address sustainable financial resources on an annual basis to effectively organize sustainable tobacco control.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135363976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NowotworyPub Date : 2023-09-05DOI: 10.5603/njo.a2023.0034
Katarzyna Różycka, Aleksandra Kapała
{"title":"Glucose metabolism disorders in cancer patients","authors":"Katarzyna Różycka, Aleksandra Kapała","doi":"10.5603/njo.a2023.0034","DOIUrl":"https://doi.org/10.5603/njo.a2023.0034","url":null,"abstract":"Diabetes and cancer are among the most frequently cited causes of disability worldwide. The pathomechanism of glycemia disorders and carcinogenesis have common features that drive each other. Diabetes is estimated to be present in 8–18% of cancer patients. Hyperglycemia and its consequences are associated with an increased risk of cancer development, disease progression, and an increased risk of death. Treatment of glucose metabolism disorders requires an individual approach regarding nutrition and lifestyle.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135363979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}